Skip to main content
This website uses cookies to ensure you get the best experience. By continuing to use this site, you agree to the use of cookies.

Please note: Your browser does not support the features used on Addgene's website. You may not be able to create an account or request plasmids through this website until you upgrade your browser. Learn more

Please note: Your browser does not fully support some of the features used on Addgene's website. If you run into any problems registering, depositing, or ordering please contact us at [email protected]. Learn more

Addgene

pLenti-EF-FH-TAZ S89A-ires-blast Citations (8)

Originally described in: Screening with a novel cell-based assay for TAZ activators identifies a compound that enhances myogenesis in C2C12 cells and facilitates muscle repair in the muscle injury model.
Yang Z, Nakagawa K, Sarkar A, Maruyama J, Iwasa H, Bao Y, Ishigami-Yuasa M, Ito S, Kagechika H, Hata S, Nishina H, Abe S, Kitagawa M, Hata Y Mol Cell Biol. 2014 Feb 18. PubMed Journal

Articles Citing pLenti-EF-FH-TAZ S89A-ires-blast

Articles
The Transcriptional Coactivator TAZ Is a Potent Mediator of Alveolar Rhabdomyosarcoma Tumorigenesis. Deel MD, Slemmons KK, Hinson AR, Genadry KC, Burgess BA, Crose LES, Kuprasertkul N, Oristian KM, Bentley RC, Linardic CM. Clin Cancer Res. 2018 Jun 1;24(11):2616-2630. doi: 10.1158/1078-0432.CCR-17-1207. Epub 2018 Mar 7. PubMed
Fascin induces melanoma tumorigenesis and stemness through regulating the Hippo pathway. Kang J, Wang J, Yao Z, Hu Y, Ma S, Fan Q, Gao F, Sun Y, Sun J. Cell Commun Signal. 2018 Jul 3;16(1):37. doi: 10.1186/s12964-018-0250-1. PubMed
The Hippo pathway effector TAZ induces TEAD-dependent liver inflammation and tumors. Hagenbeek TJ, Webster JD, Kljavin NM, Chang MT, Pham T, Lee HJ, Klijn C, Cai AG, Totpal K, Ravishankar B, Yang N, Lee DH, Walsh KB, Hatzivassiliou G, de la Cruz CC, Gould SE, Wu X, Lee WP, Yang S, Zhang Z, Gu Q, Ji Q, Jackson EL, Lim DS, Dey A. Sci Signal. 2018 Sep 11;11(547). pii: 11/547/eaaj1757. doi: 10.1126/scisignal.aaj1757. PubMed
The Hippo Pathway Effector TAZ Regulates Ferroptosis in Renal Cell Carcinoma. Yang WH, Ding CC, Sun T, Rupprecht G, Lin CC, Hsu D, Chi JT. Cell Rep. 2019 Sep 3;28(10):2501-2508.e4. doi: 10.1016/j.celrep.2019.07.107. PubMed
Luteolin suppresses epithelial-mesenchymal transition and migration of triple-negative breast cancer cells by inhibiting YAP/TAZ activity. Cao D, Zhu GY, Lu Y, Yang A, Chen D, Huang HJ, Peng SX, Chen LW, Li YW. Biomed Pharmacother. 2020 Sep;129:110462. doi: 10.1016/j.biopha.2020.110462. Epub 2020 Jul 6. PubMed
Yap/Taz promote the scavenging of extracellular nutrients through macropinocytosis. King B, Araki J, Palm W, Thompson CB. Genes Dev. 2020 Oct 1;34(19-20):1345-1358. doi: 10.1101/gad.340661.120. Epub 2020 Sep 10. PubMed
MESH1 knockdown triggers proliferation arrest through TAZ repression. Sun T, Ding CC, Zhang Y, Zhang Y, Lin CC, Wu J, Setayeshpour Y, Coggins S, Shepard C, Macias E, Kim B, Zhou P, Gordan R, Chi JT. Cell Death Dis. 2022 Mar 10;13(3):221. doi: 10.1038/s41419-022-04663-6. PubMed
Artesunate promoted anti-tumor immunity and overcame EGFR-TKI resistance in non-small-cell lung cancer by enhancing oncogenic TAZ degradation. Cao D, Chen D, Xia JN, Wang WY, Zhu GY, Chen LW, Zhang C, Tan B, Li H, Li YW. Biomed Pharmacother. 2022 Nov;155:113705. doi: 10.1016/j.biopha.2022.113705. Epub 2022 Oct 7. PubMed

If you have published an article using this material, please email us at [email protected] to have your article added to this page.